Drug Trial Radar · NCT03927157
Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma
Last checked: Nov 20, 2026Latest source record: Jul 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
405
Actual
Start
Jun 14, 2019
Primary completion
May 24, 2024
Study completion Aug 13, 2024
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Amgen
- First posted
- Apr 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Regional, Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Severe Uncontrolled Asthma
Conditions
- Asthma
Interventions
Experimental: TezepelumabBiological
Tezepelumab subcutaneous injection
PlaceboOther
Placebo subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annual Asthma Exacerbation Rate (AERR)Time frame: Randomization to Week 52
Locations
72 sites in 3 countries. Site status is shown where the registry gives one.
Research Site
Baotou, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Changchun, China
Research Site
Changsha, China
Research Site
Changsha, China
Research Site
Chengdu, China
Research Site
Chongqing, China
Research Site
Chongqing, China
Research Site
Chongqing, China
Research Site
Fuzhou, China
Research Site
Guangzhou, China
Research Site
Guangzhou, China
Research Site
Guangzhou, China
Research Site
Guangzhou, China
Research Site
Guiyang, China
Research Site
Haikou, China
Research Site
Hangzhou, China
Research Site
Hefei, China
Research Site
Hengyang, China
Research Site
Hohhot, China
Research Site
Hohhot, China
Research Site
Huzhou, China
Research Site
Jinan, China
Research Site
Jinhua, China
Research Site
Kunming, China
Research Site
Lanzhou, China
Research Site
Linhai, China
Research Site
Linyi, China
Research Site
Nanchang, China
Research Site
Nanjing, China
Research Site
Nanjing, China
Research Site
Nanjing, China
Research Site
Nanning, China
Research Site
Quanzhou, China
Research Site
Shanghai, China
Showing 40 of 72 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.